| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We examined the whole exome sequencing of 43 non-TRU-type lung adenocarcinoma specimens (tumor-normal pairs) using the next generation sequencer. As a result, in 7 of 43 cases, there were 8 kinds of nonsynonymous mutations in NKX2-1/TTF-1 gene. All of these eight NKX2-1/TTF-1 mutants were confirmed to be inactivating mutants, and TTF-1 immunostaining was negative for all 7 mutation-positive cases. KRAS mutations were confirmed in 5 of 7 cases. Histologically, 5 of 7 NKX2-1/TTF-1 mutation-positive cases were classified as invasive mucinous adenocarcinomas, and it was suggested that NKX2-1 gene mutations were involved in the developmental mechanism of non-TRU type lung adenocarcinoma.
|
